The so-called "breakthrough" pain is known for its rapid onset, intensity and short duration.
The American Cancer Society said about 800,000 cancer patients suffer from this type of pain.
Fentora gets into the bloodstream by being partially absorbed through the cheek. This method of delivery makes absorption faster when compared to similar drugs that work through the gastrointestinal tract.
The FDA approved the drug for people who can already tolerate opioid therapy for ongoing cancer pain. Possible adverse effects of the drug include decreased respiration and circulation, nausea, and fatigue.
